Research & DevelopmentMekonos closes $25M funding round for cell therapy platform

Mekonos closes $25M funding round for cell therapy platform

-

Mekonos closes funding of $25M in a series a round as it develops the future of cell therapies on a chip. The Biotech Company has developed a platform that is able to support the multiple delivery of cell payloads right down to the cell level, and allows for the physical delivery of these payloads.

Biotech Startup Mekonos raises oversubscribed $25 million after prominent research labs had promising results for the company’s developed platform for chip technology. The delivery system for the payload will be ex-vivo.

As Mekonos closes funding it has revealed plans for the use of this acquired capital. The company is planning to venture into business development, Microfluidics, MEMS among other areas.

The future of cell therapies on a chip shows the excellent ability to provide repeated and measured doses, such as CRISPR, into vulnerable cell types that include stem cells.

With this latest funding, Mekonos plans to bring change to cell therapy, an area that has not witnessed innovation in over two decades. Mekonos official stated that they are keen on disrupting existing technology in cell engineering and are making an effort to delve into personalized medicine on a large scale.

Life Sciences Voice Logo mobile
+ posts

Latest news

Top 10 Data Architecture Challenges in Modern Pharma Organizations

Executive Summary Data has become one of the most valuable strategic assets in the pharmaceutical industry. Every stage of the...

The Next Evolution of Decentralized Clinical Trials

Executive Summary Decentralized clinical trials (DCTs) emerged as one of the most significant innovations in clinical research over the past...

Despite a mid-stage miss, Mirum and Incyte strengthen the case for approval in uncommon bone disease

Incyte and Mirum Pharmaceuticals are taking a step closer to approval of their investigational pill for fibrodysplasia ossificans progressiva...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you